Breast Cancer
From the Journals
The Last 30 Days: How Oncologists’ Choices Affect End-of-Life Cancer Care
Researchers analyze data from more than 17,000 patients who died of cancer between 2012 and 2017.
From the Journals
Ancient Viruses in Our DNA Hold Clues to Cancer Treatment
Targeting remnants of a virus in our DNA could lead to more effective cancer treatment with fewer side effects.
Conference Coverage
Outcomes with CDK4/6 Inhibitors Vary in BC
A large Italian study found real-world differences in short-term outcomes among first line CDK4/6 inhibitors palbociclib, ribociclib and...
From the Journals
Which Patients With Early TNBC Can Avoid Chemotherapy?
Researchers examine breast cancer–specific survival at prespecified stromal TIL cutoffs in women with stage I TNBC who had undergone a lumpectomy...
Latest News
What Does Hormone Receptor Mean in BRCA-Associated BC?
Large international study highlights the impact of hormone receptor status in young women with BRCA-associated breast cancer.
Latest News
Black Women With Breast Cancer Face Clinical Inequities
Retrospective analysis finds no clinical trial enrollment, reduced use of targeted treatment, and shortened survival.
Latest News
Circulating Tumor DNA Hints at BC Recurrence Risk
Despite suggestive results, researchers say it’s too early to use ctDNA for adjuvant decisions in early, high-risk breast cancer.
Feature
Greater Transparency of Oncologists’ Pharma Relationships Needed
Reducing industry payments to hematologists and oncologists could benefit patients, say experts.
From the Journals
Could an EHR Nudge Reduce Unnecessary Biopsies?
The reminder system reduced the rate of sentinel lymph node biopsies in older women with early-stage breast cancer.
Conference Coverage
Cognitive Decline Minimal After Endocrine + CDK4/6 Inhibition in BC
Authors investigate cognitive functioning in the same cohort used in the SONIA trial and a matched control group of individuals that did not have...
Conference Coverage
Eribulin Similar to Taxane When Paired With Dual HER2 Blockade in BC
Patients with HER2-positive, locally advanced or metastatic breast cancer who cannot tolerate the standard taxane-based regimen have a new option...